Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry

You may also be interested in...



Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008

Japanese firm incurs “income contraction” for the first time in 17 years.

Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008

TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference

Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008

TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel